NeurologyLive Friday 5 — November 12, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: National Alzheimer Disease Registry Announced to Collect Clinical Practice Data

Announced at the 14th Clinical Trials on Alzheimer’s Disease Conference (CTAD), November 9-12, the new registry will collect routine clinical practice data from the care of patients with Alzheimer disease who are taking an FDA-approved disease-modifying therapy.

2: Detecting Demyelination and Remyelination by MRI in the Central Nervous System

In episode 5 of the NeurologyLive News Network series, "CMSC 2021: Updates in MS," Robert Zivadanov, MD, PhD, shares his thoughts on enhancing myelin regeneration and repair to counteract neurodegeneration in patients with multiple sclerosis.

3: NeuroVoices: Alexander Merkler, MD, MS, on Anticoagulants for Stroke and Ventricular Dysfunction

The assistant professor of neurology at Weill Cornell Medicine provided thoughts on his exploratory analysis, which found rivaroxaban to be superior to aspirin in reducing recurrent stroke. He discussed whether the data change how clinicians use the 2 drugs; the need for expanded, larger studies; and the realistic impact recurrent stroke has on the world today.

4: Helping Your Patients Avoid the Migraine Trigger Trap

Forget what you think you know about red wine or chocolate ‘activating’ migraine. Many commonly accepted “triggers” aren’t triggers at all. Michael Marmura, MD, associate professor and director of Outpatient Operations, Jefferson Headache Center; and co-chief, Division of Headache, Jefferson University Hospital, writes offering his insight to clinicians treating migraine.

5: Greatest Recent Advancements in MS, Looking Toward the Future: Ilya Kister, MD

The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year, and to find out why patients with MS should continue to have hope in the coming years.

—————————————————
Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

  • Nominations are open through January 31, 2022
  • The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
  • Nominees will be selected on the merits of their lifetime work.
  • One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
  • The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.